|
Live In Play®
Updated: 15-May-26 06:04 ET SPRY:
ARS Pharmaceuticals reports first quarter 2026 financial results and corporate update
(7.94)
Q1 2026 total revenue of $22.7 million including
neffy
®
(epinephrine nasal spray)
U.S. net product
revenue of $17.5 million
|
